Navigation Links
Genesis Biopharma Announces Management and Board Changes
Date:2/11/2011

LOS ANGELES, Feb. 11, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Anthony J. Cataldo has been named President and Chief Executive Officer.  Mr. Cataldo succeeds Robert Brooke, who now serves as a strategic advisor to Genesis Biopharma.  In addition, the Company named Michael Handelman as Chief Financial Officer, Treasurer and Secretary, succeeding Richard McKilligan.

Mr. Cataldo and Mr. Handelman have been appointed to the Company's Board of Directors.  Mr. Brooke, Mr. McKilligan and Mark Ahn have resigned as members of the Genesis Biopharma Board.  All of these changes are effective immediately.

"I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value," said Mr. Cataldo. "Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralizes a key cancer defense mechanism that is over-expressed in more than 80% of tumors. The anti-CD55 technology could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development."

Mr. Cataldo, age 58, has nearly two decades experience as a senior executive with publicly traded companies.  He currently serves as the Chairman, Chief Executive Officer and a Director of Oxis International, Inc. (OTC Bulletin Board: OXIS), positions he has held since March 2009.  Oxis is engaged in the research, development and sale of products that counteract the harmful effects of oxidative st
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/18/2014)... , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... on Friday, August 22 at 2:00 pm ET.  ... CEO, will provide a brief review of SQI,s recent ... , a diagnostics industry veteran recently appointed to the ...
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter ended September 30,2010 on Wednesday, November 3, 2010 ... a live webcast and conference call at 5:00 p.m. Eastern ... and webcast to discuss financial results and recent business highlights. ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
... the Human Genome -- REYKJAVIK, Iceland, October 27, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
(Date:8/20/2014)... discovered that acral melanomas the rare type of skin ... genetically distinct from other more common types of skin cancer, ... journal Pigment Cell & Melanoma Research . , Acral ... of the feet, nail-beds and other hairless parts of the ... caused by UV damage from the sun. , The team, ...
(Date:8/20/2014)... Wu Feng has built upon a National Science Foundation ... Cloud" program, and synergistically complemented it with subsequent collaborative ... Force on "big computing" for mini-drones and a $1 ... Health on "big data" for the life sciences. , ... each grant, he was able to tell a much ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... of Texas at Dallas researcher and a university-affiliated biomedical ... a long-term cure for tinnitus. Described as a ... 40 percent of recently returned military veterans and about ... The U.S. Veterans Administration spends about $1 billion a ...
... Assistant Professor, Department of Microbiology and Molecular Genetics, School ... by the American Society for Microbiology (ASM) to receive ... the ASM, this award recognizes an early career scientist ... Dr. Raffatellu earned her M.D. at the University ...
... ingredient in the venom of the "deathstalker" scorpion could help ... are reporting. The substance allows therapeutic genes genes that ... current approaches, according to the study in ACS Nano ... that gene therapy the delivery of therapeutic genes into ...
Cached Biology News:Tinnitus study looks for cure to 'ringing in the ears' 2Tinnitus study looks for cure to 'ringing in the ears' 3